Prot#GS-US-264-0106: A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fuma

Project: Research project

Project Details

StatusFinished
Effective start/end date3/15/11 → 3/15/14

Funding

  • Gilead Sciences, Inc (GS-US-264-0106)